NCT06245798

Liver Resection for Patients With Hepatocellular Carcinoma and Clinically Significant Portal Hypertension

Liver Resection for Patients With Hepatocellular Carcinoma and Clinically Significant Portal Hypertension: A Chinese Multicentre Retrospective Cohort Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 3,000 (actual)
• Sponsor: Tang-Du Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: —

Summary

Clinically significant portal hypertension limits the therapeutic options for hepatocellular carcinoma (HCC), which is closely associated with patient prognosis. HCC patients with CPSH are heterogeneous and treatment allocation remains controversial. The aim of this study was to compare the survival benefits of liver resection (LR) and transarterial chemoembolisation (TACE) in these populations.

Conditions

• Hepatic Carcinoma

Interventions

Type	Name	Description
PROCEDURE	transarterial chemoembolisation	During transarterial chemoembolisation（TACE）, a vascular catheter was selectively inserted into the tumour-feeding artery with an injection containing a mixture of doxorubicin (10-50 mg) and lipiodol (2-20 mL), followed by embolisation using gelatin sponge particles. TACE was repeated when residual viable tumours were confirmed or new lesions developed in patients with adequate liver function

Timeline

• Start date: 2023-01-01
• Primary completion: 2023-04-01
• Completion: 2023-12-01
• First posted: 2024-02-07
• Last updated: 2024-02-07

Locations

2 sites across 1 country: China